Hikma Pharmaceuticals Plc Director/PDMR Shareholding (4832S)
March 17 2016 - 11:25AM
UK Regulatory
TIDMHIK
RNS Number : 4832S
Hikma Pharmaceuticals Plc
17 March 2016
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 17 March 2016: Hikma Pharmaceuticals PLC (LSE: HIK)
(NasdaqDubai: HIK) announces that the Remuneration Committee has
made the following conditional awards under the Hikma
Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to
Persons Discharging Managerial Responsibility ("PDMR") of the
Company.
Awards under the EIP were made on 17 March 2016 at a price of
1,815 pence per Ordinary Share (being the closing price the day
before grant) as follows:
PDMR Element B Element C
Shares Shares
Said Darwazah 68,346 45,100
Mazen Darwazah 38,501 25,406
Bassam Kanaan 26,090 26,090
Majda Labadi 14,530 14,530
Riad Mishlawi 19,890 19,890
Khalid Nabulsi 20,400 20,400
Mike Raya 29,484 29,484
Susan Ringdal 15,730 15,730
The Element B share awards will be released to the participants
in two years from the date of grant subject to their continued
employment and the non-occurrence of forfeiture events during the
vesting period as judged by the Remuneration Committee at each
anniversary of the grant.
The Element C share awards will be released to the participants
in three years from the date of grant subject to their continued
employment.
These participants are must retain 50% of the vested shares
under elements B and C until five years from the date of grant.
Further details on the EIP, forfeiture criteria and holding
period can be found in Hikma's report and accounts for the year
ended 31 December 2014 on pages 98, 103 and 104.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs +44 20 7399 2760
Company Secretary
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2015, Hikma achieved
revenues of $1,440 million and profit attributable to shareholders
of $252 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBUGDXXDBBGLR
(END) Dow Jones Newswires
March 17, 2016 11:25 ET (15:25 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024